-$0.47 EPS Expected for Arcus Biosciences Inc (NYSE:RCUS) This Quarter

Equities research analysts forecast that Arcus Biosciences Inc (NYSE:RCUS) will post earnings of ($0.47) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Arcus Biosciences’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.47). Arcus Biosciences posted earnings per share of ($0.25) in the same quarter last year, which would suggest a negative year over year growth rate of 88%. The company is scheduled to report its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Arcus Biosciences will report full-year earnings of ($2.01) per share for the current financial year, with EPS estimates ranging from ($2.02) to ($1.99). For the next financial year, analysts forecast that the company will post earnings of ($2.22) per share, with EPS estimates ranging from ($2.36) to ($2.08). Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Arcus Biosciences.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.24). Arcus Biosciences had a negative return on equity of 30.67% and a negative net margin of 736.31%. The company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $4.54 million.

A number of research firms have commented on RCUS. ValuEngine upgraded shares of Arcus Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Svb Leerink restated an “outperform” rating on shares of Arcus Biosciences in a research report on Friday, May 3rd. Zacks Investment Research downgraded shares of Arcus Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. Finally, Citigroup dropped their price target on shares of Arcus Biosciences from $25.00 to $15.00 and set an “in-line” rating on the stock in a research report on Wednesday, June 5th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $16.56.

In other Arcus Biosciences news, President Juan C. Jaen acquired 15,000 shares of the stock in a transaction dated Friday, June 28th. The shares were bought at an average price of $7.59 per share, with a total value of $113,850.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Terry J. Rosen acquired 41,540 shares of the stock in a transaction dated Tuesday, June 4th. The stock was acquired at an average cost of $7.91 per share, for a total transaction of $328,581.40. The disclosure for this purchase can be found here. Insiders have acquired a total of 140,343 shares of company stock worth $1,120,078 over the last 90 days. 19.23% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new stake in shares of Arcus Biosciences in the 2nd quarter worth about $119,000. Citadel Advisors LLC grew its holdings in shares of Arcus Biosciences by 296.9% in the 2nd quarter. Citadel Advisors LLC now owns 69,537 shares of the company’s stock worth $553,000 after purchasing an additional 52,018 shares during the last quarter. Cubist Systematic Strategies LLC bought a new stake in shares of Arcus Biosciences in the 2nd quarter worth about $163,000. Morgan Stanley grew its holdings in shares of Arcus Biosciences by 879.2% in the 2nd quarter. Morgan Stanley now owns 98,806 shares of the company’s stock worth $785,000 after purchasing an additional 88,716 shares during the last quarter. Finally, EcoR1 Capital LLC grew its holdings in shares of Arcus Biosciences by 50.3% in the 2nd quarter. EcoR1 Capital LLC now owns 1,488,205 shares of the company’s stock worth $11,787,000 after purchasing an additional 498,059 shares during the last quarter. 46.59% of the stock is currently owned by institutional investors.

Shares of RCUS stock traded up $0.26 during midday trading on Friday, reaching $7.37. 2,757 shares of the company were exchanged, compared to its average volume of 139,282. Arcus Biosciences has a 12 month low of $6.30 and a 12 month high of $16.06. The company has a market cap of $339.28 million, a P/E ratio of -5.16 and a beta of 1.02. The company’s 50 day moving average price is $7.95 and its two-hundred day moving average price is $9.96.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.

Featured Story: Bear Market

Get a free copy of the Zacks research report on Arcus Biosciences (RCUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcus Biosciences (NYSE:RCUS)

Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.